Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a long-term extension study titled A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis. The study aims to assess the safety and efficacy of amlitelimab in individuals with moderate to severe atopic dermatitis who participated in prior amlitelimab trials. This research is significant as it seeks to provide insights into the long-term effects and potential benefits of amlitelimab for patients with this chronic skin condition.
The intervention being tested is amlitelimab, administered via subcutaneous injection. It is designed to treat moderate to severe atopic dermatitis, with additional treatments including topical corticosteroids, topical calcineurin inhibitors, and oral corticosteroids.
This interventional study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. Participants will receive regular visits every four weeks, with some allowed remote or home dosing. The study includes both responder and non-responder participants from previous trials, with specific protocols for drug withdrawal and treatment restoration based on response.
The study began on August 22, 2022, and is currently recruiting participants. The last update was submitted on July 8, 2025. These dates are crucial as they indicate the study’s progression and ongoing nature, providing a timeline for potential results and further updates.
The update on this study could influence Sanofi’s stock performance and investor sentiment, as positive results may enhance the company’s market position in dermatological treatments. Investors should monitor this study’s outcomes, as they could impact Sanofi’s competitive standing in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.